07:00 , Aug 29, 2005 |  BioCentury  |  Finance

Ebb & Flow

Dov (DOVP) fell $2.98 (17%) to $14.99 on 5.2 million shares on Friday after suspending dosing in a Phase III trial of ocinaplon to treat generalized anxiety disorder. The suspension followed enzyme elevations in liver...
08:00 , Nov 1, 2004 |  BC Week In Review  |  Company News

Myriad Genetics management update

Myriad Genetics Inc. (MYGN), Salt Lake City, Utah   Business: Pharmacogenetics   Hired: Mark Anderson as VP of chemistry at MYGN's Myriad Pharmaceuticals Inc. subsidiary, formerly director of medicinal chemistry at Elitra Pharmaceuticals Inc. ;...
07:00 , Sep 27, 2004 |  BC Week In Review  |  Company News

AlgoRx management update

AlgoRx Pharmaceuticals Inc. , Secaucus, N.J.   Business: Neurology   Hired: Paul Hamelin as president and COO, formerly president and CEO of Elitra Pharmaceuticals Inc.  ...
07:00 , May 31, 2004 |  BioCentury  |  Product Development

Cracking antifungals

For decades, the mainstays for treating fungal infections have come from two compound classes: azoles, which were introduced in the late 1960s, and polyenes, which were introduced in the 1950s. Today, there are two additional...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Company News

Elitra management update

Elitra Pharmaceuticals Inc. , San Diego, Calif.   Business: Infectious diseases   Promoted: Paul Hamelin to CEO and a director, from COO, while remaining president; he replaces Harry Hixson, who remains chairman  ...
07:00 , Jun 26, 2003 |  BC Extra  |  Company News

Elitra promotes Hamelin to CEO

Antibacterial company Elitra (San Diego, Calif.) promoted Paul Hamelin to CEO and a director from COO. He retains his title of president and replaces former CEO Harry Hixson, who remains chairman....
08:00 , Feb 24, 2003 |  BC Week In Review  |  Company News

Elitra, Kaken Pharmaceutical Co. Ltd. deal

The companies partnered to develop anti-fungal therapeutics. Elitra will conduct high throughput screening against targets and is responsible for certain preclinical development efforts. Kaken also will contribute to preclinical development, and both companies will coordinate...
08:00 , Jan 20, 2003 |  BC Week In Review  |  Company News

Sequenom board of directors update

Sequenom Inc. (SQNM), San Diego, Calif.   Business: Diagnostics/Imaging, High throughput screening   Appointed: Harry Hixson, chairman and CEO of Elitra Pharmaceuticals Inc.  ...
08:00 , Dec 9, 2002 |  BioCentury  |  Finance

Tracking Millennium's departures

Tracking Millennium's departures Name Week departed (new company) Position at MLNM Notes Charles Homcy 12/9/02 President of R&D Joined MLNM in 2002 via Cor acquisition; will continue to sit on MLNM's board John Maraganore 12/9/02...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Company News

Nereus management update

Nereus Pharmaceuticals Inc. , San Diego, Calif.   Business: Cancer, Infectious diseases, Autoimmune/Inflammation   Hired: Deborah Mosca as VP of research, formerly VP of drug development at Elitra Pharmaceuticals Inc.  ...